Incb3344
WebINCB3344 Medical Subject Headings (MeSH) 2.3.2 Depositor-Supplied Synonyms INCB3344 709018-37-1 N- (2- ( ( (3S,4S)-1- (4- (Benzo [d] [1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4 … WebINCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 …
Incb3344
Did you know?
WebINCB3344 is a novel potent and selective antagonist of CCR2 receptor, which possesses an IC 50 of 10 nM for CCL2. [1] CCR2 is a chemokine receptor mainly expressed on … WebINCB3344 is a novel potent and selective antagonist of CCR2 receptor, which possesses an IC 50 of 10 nM for CCL2. [1] CCR2 is a chemokine receptor mainly expressed on monocytes which acts as the key receptor in mediating their tissue influx in the context of immune-based inflammation.
WebNov 19, 2024 · INCB3344 is a selective CCR2 antagonist which blocks the CCL2/CCR2 axis. SCH527123 is a selective, small-molecule CXCR2 antagonist which blocks the CXCL1/CXCR2 axis. After diethylnitrosamine treatment for 6 weeks, the rats were divided into 4 treatment groups consisting of 10 animals per group. The rats were anesthetized … WebMar 12, 2024 · CCR2 inhibitor INCB3344 was subcutaneously injected for two months (Med Chem Express, Monmouth Junction, NJ, USA, 100 mg/kg/day). 2.2. H&E and sirius red staining, immunohistochemistry. Livers were fixed in 10% phosphate-buffered formalin acetate at 4 °C overnight and embedded in paraffin wax. Paraffin sections (5 mm) were …
INCB3344 is a potent, selective and orally bioavailable CCR2 antagonist with IC50 values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity. CAS No. 1262238-11-8 Purity & Quality Control Other CCR Products Cabotegravir (GSK1265744) New WebMar 6, 2024 · Radiotherapy, including brachytherapy, is a major therapeutic regimen for cervical cancer. Radioresistance is a decisive factor in radiation treatment failure. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) in the tumor microenvironment are critical factors in the curative effects of cancer therapies. However, …
WebSep 18, 2009 · To investigate the kinetics of INCB3344 binding to hCCR2, a single concentration of 10 nM 3 H-INCB3344 was incubated with 10 μg of HEK293/hCCR2 cell membranes in the presence or absence of excessive amounts of the unlabeled compound for different periods of time. Rapid binding was observed within the first 20 min, with a T …
WebJan 4, 2006 · INCB3344 was synthesized by the medicinal chemistry department of Incyte Corp. The specificity of this compound for CCR2 and its pharmakinetics of INCB3344 have been described elsewhere . Metabolic testing. Insulin tolerance testing was carried out in animals that were fasted for 6 hours beginning at approximately 10 am. shared secret steam как получитьWebINCB3344 is an effective, specific and orally bioavailable CCR2 antagonist with IC50 values of 9.5 nM (mCCR2) and 5.1 nM (hCCR2) in binding antagonism and 7.8 nM (mCCR2) and in 3.8 nM (hCCR2) antagonism of chemotaxis activity. Characterization of the pharmacological activity of INCB3344 is first evaluated by testing its ability to inhibit CCL2 ... shared secretsWebSep 1, 2009 · INCB3344 was first published as a small molecule nanomolar inhibitor of rodent CCR2. Here, we show that INCB3344 can also bind human CCR2 (hCCR2) with high affinity, having a dissociation... shared secret vpn uzhWebINCB3344 is a potent and selective antagonist of CCR2 receptor with IC(50) values of 5.1 nM (hCCR2) and 9.5 nM (mCCR2) in binding antagonism and 3.8 nM (hCCR2) and 7.8 nM (mCCR2) in antagonism of chemotaxis activity. INCB3344 exhibited >100-fold selectivity over other homologous chemokine receptors, a free fraction of 24% in human serum and … sharedsection registryWebMar 3, 2024 · Association and dissociation kinetics of 5 nM [ 3 H]INCB3344 binding to membranes of CHO cell membranes transiently expressing murine CCR2 at 25 °C. Dissociation was initiated by the addition of... sharedsection 意味WebAdam Hardy is an academic researcher from GlaxoSmithKline. The author has contributed to research in topic(s): Docking (molecular). The author has an hindex of 1, co-authored 1 publication(s) receiving 95 citation(s). shared secret とはWebApr 13, 2011 · For analysis of the effects of INCB3344 on mRNAs encoding proinflammatory mediators or on ERK1/2 phosphorylation in the spinal cord of SN-CCI rats, animals received three intrathecal injections of INCB3344 or vehicle, at 24 h intervals, between 15 and 17 d after injury. Tissues were collected 5 h after the last injection. sharedsection 1024、12288、512